{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:34:00Z","timestamp":1782552840722,"version":"3.54.5"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Wir berichten von einer 32-j\u00e4hrigen Patientin mit Colitis ulcerosa, die unter Therapie mit dem JAK(Januskinase)-Inhibitor Tofacitinib eine massive papulopustul\u00f6se Dermatitis entwickelt hat. Trotz intensiver lokaltherapeutischer Ma\u00dfnahmen und der Einnahme von Kortikosteroiden und Doxycyclin trat keine ausreichende Besserung ein, sodass die Tofacitinib-Behandlung beendet werden musste. Bekannterma\u00dfen kann die Klasse der JAK-Inhibitoren zu infekti\u00f6sen und allergischen Hautnebenwirkungen f\u00fchren. F\u00e4lle von steriler papulopustul\u00f6se Dermatitis unter Therapie mit JAK-Inhibitoren sind allerdings bislang kaum berichtet worden.<\/jats:p>","DOI":"10.1007\/s00105-021-04793-6","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T12:02:40Z","timestamp":1616587360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Granulomat\u00f6se rosazeaartiges Exanthem unter Tofacitinib","Granulomatous rosacea-like dermatitis under therapy with tofacitinib"],"prefix":"10.1007","author":[{"given":"Kristina","family":"Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"4793_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky\u00a0W, King\u00a0BA (2017) JAK inhibitors in dermatology: the promise of a\u00a0new drug class. J\u00a0Am Acad Dermatol 76:736\u2013744","journal-title":"J Am Acad Dermatol"},{"key":"4793_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjd.17149","volume":"180","author":"BE Strober","year":"2019","unstructured":"Strober\u00a0BE, Gottlieb\u00a0AB, van de Kerkhof\u00a0PCM, Puig\u00a0L, Bachelez\u00a0H, Chouela\u00a0E, Imafuku\u00a0S, Tha\u00e7i\u00a0D, Tan\u00a0H, Valdez\u00a0H, Gupta\u00a0P, Kaur\u00a0M, Frajzyngier\u00a0V, Wolk\u00a0R (2019) Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. Br J Dermatol 180:67\u201375","journal-title":"Br J Dermatol"},{"key":"4793_CR3","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","volume":"379","author":"K Papp","year":"2018","unstructured":"Papp\u00a0K, Gordon\u00a0K, Tha\u00e7i\u00a0D, Morita\u00a0A, Gooderham\u00a0M, Foley\u00a0P, Girgis\u00a0IG, Kundu\u00a0S, Banerjee\u00a0S (2018) Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N\u00a0Engl J Med 379:1313\u20131321","journal-title":"N Engl J Med"},{"key":"4793_CR4","first-page":"8385","volume":"17","author":"T Li","year":"2018","unstructured":"Li\u00a0T, Zeng\u00a0Q, Chen\u00a0X, Wang\u00a0G, Zhang\u00a0H, Yu\u00a0A, Wang\u00a0H, Hu\u00a0Y (2018) The therapeutic effect of artesunate on rosacea through the inhibition of the JAK\/STAT signaling pathway. Mol Med Rep 17:8385\u20138390","journal-title":"Mol Med Rep"},{"key":"4793_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1365-2133.2005.06659.x","volume":"153","author":"S Gellrich","year":"2005","unstructured":"Gellrich\u00a0S, Muche\u00a0JM, Wilks\u00a0A, Jasch\u00a0KC, Voit\u00a0C, Fischer\u00a0T, Audring\u00a0H, Sterry\u00a0W (2005) Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B\u2011cell lymphomas\u2014an applicational observation. Br J Dermatol 153:167\u2013173","journal-title":"Br J Dermatol"},{"key":"4793_CR6","first-page":"195","volume":"9","author":"R Gutzmer","year":"2011","unstructured":"Gutzmer\u00a0R, Becker\u00a0JC, Enk\u00a0A, Garbe\u00a0C, Hauschild\u00a0A, Leverkus\u00a0M, Reimer\u00a0G, Treudler\u00a0R, Tsianakas\u00a0A, Ulrich\u00a0C, Wollenberg\u00a0A, Homey\u00a0B (2011) Management of cutaneous side effects of EGFR inhibitors: recommendations from a\u00a0German expert panel for the primary treating physician. J\u00a0Dtsch Dermatol Ges 9:195\u2013203","journal-title":"J Dtsch Dermatol Ges"},{"key":"4793_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/ajd.12124","volume":"55","author":"R Anforth","year":"2014","unstructured":"Anforth\u00a0R, Liu\u00a0M, Nguyen\u00a0B, Uribe\u00a0P, Kefford\u00a0R, Clements\u00a0A, Long\u00a0GV, Fernandez-Pe\u00f1as\u00a0P (2014) Acneiform eruptions: a\u00a0common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol 55:250\u2013254","journal-title":"Australas J Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04793-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-021-04793-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04793-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T12:04:06Z","timestamp":1616587446000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-021-04793-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":7,"alternative-id":["4793"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04793-6","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"23 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Neumann und P.\u00a0Terheyden geben an, dass kein Interessenkonflikt besteht. D.Tha\u00e7i hat f\u00fcr Vortragst\u00e4tigkeit Honorare von Pfizer erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}